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In vitro and pilot in vivo imaging of 18 kDa 
translocator protein (TSPO) in inflammatory 
vascular disease
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Abstract 
Background: Inflammatory vascular disease of the arteries, such as inflamed atheromatous plaques or arteritis, may 
cause aneurysms or ischemic strokes. In this context, using positron emission tomography (PET) to image inflamma‑
tion may help select patients who would benefit from appropriate therapeutic interventions. This study sought to 
assess the usefulness of the 18 kDa translocator protein (TSPO) tracers  [11C]‑PBR28 and  [18F]‑PBR06 for imaging inflam‑
matory vascular disease in vitro and in vivo. Immunohistochemistry for macrophage infiltration as well as autoradiog‑
raphy with  [18F]‑PBR06 were performed on eight paraffin‑embedded, formalin‑fixed atherosclerosis plaques pro‑
spectively collected after carotid endarterectomy of eight patients affected by ischemic stroke. Six different patients, 
one of whom was also included in the in vitro study, underwent PET imaging. Two patients with carotid stenosis 
associated with ischemic stroke were imaged with  [18F]‑PBR06 PET/CT, and four other patients (three with large vessel 
vasculitis and one with bilateral carotid stenosis but without stroke) were imaged with  [11C]‑PBR28.
Results: All in vitro sections showed specific binding of  [18F]‑PBR06, which co‑localized with immunohistochemistry 
markers for inflammation. However, in vivo TSPO imaging with either  [11C]‑PBR28 or  [18F]‑PBR06 was negative in all 
participants.
Conclusion: Despite good uptake on surgical samples in vitro,  [11C]‑PBR28 and  [18F]‑PBR06 are not viable clinical 
tools for imaging inflammatory vascular disease.
Trial registration: NCT02513589, registered 31 July 2015 and NCT00547976, registered 23 October 2007. https:// clini 
caltr ials. gov.
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Background
Inflammation in the vascular wall plays an important 
role in the pathophysiology of atherosclerosis, includ-
ing the development of plaque, plaque destabilization, 
and rupture. In the carotid artery, a plaque may become 
symptomatic when it suddenly swells or promotes the 
formation of thrombosis and downstream embolism. 
As an example, stenosing atherosclerotic disease in the 
carotid artery is present in a large number of stroke 
patients [1]. In addition, large vessel vasculitis, such as 
Takayasu’s arteritis and Giant Cell arteritis, is character-
ized by a cellular immune response involving T cells and 
macrophages [2]. These conditions are challenging from 
a diagnostic perspective, because arteritis affecting the 
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aortic arch may delay the clinical diagnosis of potentially 
life-threatening alterations in hemodynamic parameters.
In this context, a noninvasive method of detecting 
inflammatory activity, such as the accumulation of mac-
rophages, in arteries would be of great clinical value to 
orient prognosis, direct therapy, and assess novel thera-
pies. While standard imaging modalities can quantify the 
degree of stenosis and the thickness of an inflamed arte-
rial wall, they cannot directly identify an inflammatory 
component. The positron emission tomography (PET) 
tracer  [18F]-FDG, is clinically used to diagnose vascular 
inflammation [3, 4] but may also aspecifically accumulate 
in any metabolically active tissues or cells. Radiopharma-
ceuticals targeting 18 kDa translocator protein (TSPO), a 
protein heavily expressed in macrophages, may identify 
the presence of inflammation in the vascular wall more 
specifically and perhaps earlier. Indeed, recent findings 
underscored the interest of TSPO imaging in inflamed 
plaque, because TSPO co-localized with a subset of 
CD11b + macrophages which are recruited in advanced 
atherosclerotic lesions [5]. Pilot comparative studies sug-
gest the superiority of TSPO-based radiopharmaceutical 
to image vulnerable plaque vs  [18F]-FDG [6]. For instance, 
ex  vivo autoradiography with  [3H]-PK11195 suggests 
that TSPO-imaging of macrophages in atherosclerotic 
plaque may be feasible [7]. In humans, PET imaging with 
 [11C]-(R)-PK11195 correlated well with  [3H]-PK11195 
binding in ex vivo samples [8]. Additionally, PET imaging 
with  [11C]-(R)-PK11195 differentiated symptomatic from 
asymptomatic patients with atherosclerosis [8]. However, 
PK11195 has moderate affinity for TSPO and low specific 
binding [9]. Thus, recently developed TSPO radioligands 
with higher affinity for the target [10] may be more useful 
for in vivo imaging of vascular wall inflammation. Among 
these recently developed radioligands,  [18F]-PBR06 has 
been successfully used in mice to image macrophage 
infiltration in atherosclerotic plaques, but no human 
imaging has been performed so far [11].
This study sought to assess the feasibility of using 
second generation TSPO imaging to identify vascular 
inflammation by performing  [18F]-PBR06 autoradiogra-
phy on surgical samples collected from unstable carotid 
plaques. In addition, patients with inflamed carotid 
plaques and large vessel vasculitis were scanned using 




Atherosclerotic plaque samples were collected after 
carotid endarterectomy in eight patients affected by 
ischemic stroke (Table 1).
Asterisks identify the patient who had a PET scan after 
his surgical sample was analyzed in vitro. Affinity bind-
ing genotype was unknown for some participants in the 
in vivo part of the study because they were imaged before 
the different binding affinity classes were discovered.
One sample was from a participant with high-affin-
ity binding to the TSPO protein [12], three were from 
mixed-affinity binders, and one was from a low-affinity 
Table 1 Characteristics of patients in the in vitro and in vivo parts of the study
Patients Age (years) Sex Stenosis localization Stenosis degree TSPO affinity
In vitro
 1 83 Male Right internal carotid (IC) 70% N/A
 2 51 Male Left IC 80% N/A
 3 87 Male Right IC 70% N/A
 4 66 Male Right IC 60% High Binder
 5 78 Male Right IC 90% Mixed Binder
 6 79 Male Left IC 50% Low Binder
 7* 81 Male Right IC 60% Mixed Binder
 8 76 Male Right IC 75% Mixed Binder
In vivo
 1* 81 Male Right IC 60% Mixed Binder
 2 57 Male Right IC 90% High Binder
 3 78 Male Bilateral IC 75% and 85% N/A
 4 67 Female Bilateral Temporal Arteritis N/A
 5 76 Female Bilateral Temporal Arteritis N/A




Page 3 of 7Schollhammer et al. EJNMMI Res           (2021) 11:45  
binder; genotype was not determined in the remaining 
three participants. After embedding the samples in par-
affin and fixing in formalin, four adjacent sections were 
used: one for hematoxylin eosin saffron (HES) staining, 
one for immunohistochemistry, and two for autoradiog-
raphy, which were used to calculate specific and nonspe-
cific TSPO binding, respectively.
In both the in  vitro and in  vivo studies, all partici-
pants gave written informed consent. Participation 
was approved by either the ethical committee of the 
University of Bordeaux, France (CNIL, declaration 
number 1858342v0, 11/05/2015 and CPP DC2015/01 
on 12/02/2015 for the in  vitro study and 2016/95, 
on 21/12/2016 for the in  vivo study, Clinical Trial 
NCT02513589), where the  [18F]-PBR06 scans were con-
ducted, or by the Institutional Review Board (IRB) of the 
National Institute of Mental Health (NIMH) in Bethesda, 
Maryland, USA (Clinical Trial NCT00547976), where the 
 [11C]-PBR28 scans were conducted.
Immunohistochemistry
The immunohistochemical study was performed using 
an automated immunostainer (Dako A/S, Glostrup, Den-
mark), after heat-induced retrieval in citrate buffer with 
antibodies against α-smooth muscle actin (α-SMA, clone 
1A4, 1/100), h-caldesmon (clone h-Cd, 1/100), CD45 
(clone 2B11, 1/100), CD3 (polyclonal, 1/200), and CD68 
(clone PGM1, 1/100) (Dako Omnis). The epitopes were 
detected using the Envision+ system horseradish peroxi-
dase detection kit and revealed with liquid diaminoben-
zidine (Dako Omnis).
α-SMA and h-caldesmon stains were used to quantify 
the percentage of the fibrous rupture of the tunica media 
of the muscular arteries. α-SMA stains also evaluated the 
infiltration of myofibroblasts in the intima. CD45, CD3, 
and CD68 stains assessed the count of leukocytes, T lym-
phocytes, and macrophages per 10 high magnification 
(× 400) fields, respectively.
Autoradiography
As previously described [13, 14], after dewaxing, rehydra-
tion, and unmasking, samples were incubated for 60 min 
with a binding solution containing 1  MBq/300  µL of 
 [18F]-PBR06. To assess non-specific binding, a > 100-fold 
excess (1 μM) of cold compound  [natF]-PBR06 was added 
in adjacent slices. Samples were then rinsed for 10 min in 
Tris-buffered saline and distilled water and dried using 
air stream. Autoradiographic images were acquired over 
60 min using a BetaImager-2000 (BiospaceLab, Nesles-la-
Vallée, France).
After fusion by affine transformation of HES and auto-
radiographic images, regions of interest (ROIs) were used 
to calculate the amount of specific binding. A first ROI 
was drawn on the carotid tissue (whole plaque or mac-
rophage compartment or smooth-muscle compartment) 
to estimate total binding and a second one, correspond-
ing to background noise, was placed around the tissue. 
The same ROIs were then transferred to the adjacent 
slice to determine nonspecific binding. After subtract-
ing background noise, specific binding was expressed as a 
percentage over total binding.
In vivo study
Patients
Six patients were scanned (Table 1). Two patients suffer-
ing from ischemic stroke were scanned with  [18F]-PBR06 
(one of these was included in the in vitro portion of this 
study). Another patient with bilateral carotid stenosis, 
but without stroke, was scanned with  [11C]-PBR28. In 
addition, three patients with large vessel vasculitis (two 
with Giant Cell arteritis and one with Takayasu’s arteri-
tis) were scanned with  [11C]-PBR28.
CT angiography, PET/CT acquisitions, and analysis
CT angiography was performed with a General Electric 
Optima 600, using Omnipaque 350 as contrast agent.
[18F]-PBR06 scans were performed with a Discovery 
RX PET/CT machine (General Electric Medical System) 
at the University Hospital of Bordeaux, France. Dynamic 
cervical PET/CT dynamic images were acquired over 
90  min (27 frames composed of 6 × 30  s, 3 × 1  min, 
2 × 2 min and 16 × 5 min) after intravenous administra-
tion of 166.8 ± 6.3 MBq of  [18F]-PBR06. The images were 
reconstructed using an ordered-subset expectation maxi-
mization algorithm, and the CT scan was used for atten-
uation correction.
[11C]-PBR28 scans were performed with an Advance 
PET/CT machine (General Electric Medical System) at 
the NIH Clinical Center in Bethesda, Maryland, USA. 
After injection of 700  MBq ± 29  MBq of  [11C]-PBR28, 
dynamic cervical PET/CT images were acquired 
over 120  min for the patient with carotid stenosis (33 
frames composed of 6 × 30  s, 3 × 1  min, 2 × 2  min and 
22 × 5  min), and an acquisition from the head to mid-
thigh was performed for the three participants with large 
vessel disease (dynamic scan composed of 4 bed posi-
tions of 4 frames x 15  s, 3 × 30  s, 3 × 1  min, 3 × 2  min, 
and 4 × 4 min). The images were reconstructed using an 
ordered-subset expectation maximization algorithm, and 
attenuation correction was achieved with a 68Ge rotating 
pin source.
Statistical analysis
Mean signal for unblocked and blocked samples were 
compared using the Wilcoxon test for paired samples. 
Significance was set at p < 0.05 (two-tailed). Statistics 
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were performed using GraphPad Prism software (v6.01, 




Immunostaining consistently showed large infiltra-
tion of inflammatory cells in the artery wall. For leuko-
cytes, nine to 360 cells were stained using CD45. For T 
lymphocytes, eight to 261 cells were stained using CD3. 
For macrophages, 82 to 286 were stained using CD68. 
α-SMA stained one to 30 intimal myofibroblasts and 
smooth muscle cells. The fibrous changes of the tunica 
media ranged between 10 and 60% of the wall circumfer-
ence (Figs. 1 and 2).
Autoradiography
All samples showed  [18F]-PBR06 binding that co-localized 
with immunohistochemistry staining for macrophages 
(Figs. 2 and 3) and was displaced by the cold compound 
(the mean absolute count was 17.65 ± 15.01 cps/mm2 for 
total binding vs 11.04 ± 7.81  cps/mm2 for blocked sam-
ples, p = 0.0078).
Specific binding was 64% of total binding in the high-
affinity binding patient, 27% on average in the mixed-
affinity binders, and 13% in the low-affinity binding 
patient. The average of all eight samples was 38 ± 20% 
(Fig. 4).
Interestingly, macrophages area and the smooth muscle 
had similar amount of specific binding.
Fig. 1 Immunohistochemistry scoring of h‑caldemon, α‑smooth 
muscle actin (α‑SMA), CD45, CD3 and CD68 investigated in this study. 
α‑SMA and h‑caldesmon stains were used to quantify the percentage 
of the fibrous rupture of the tunica media of the muscular arteries 
CD45, CD3, and CD68 stains assessed the count of leukocytes, T 
lymphocytes, and macrophages per 10 high magnification (× 400) 
fields, respectively
Fig. 2 [18F]‑PBR06 autoradiography at baseline (a) and after pre‑incubation with cold  [natF]‑PBR06 (b) and HES anatomical sections (c) in a piece 
of carotid endarterectomy. A large atheromatous plaque with calcification invaded the intima and tunica media of the arterial wall (d, × 25). 
Immunohistochemistry showed destruction of the tunica media by the plaque (e, × 25), macrophage infiltration around the cholesterol clefts (f, 
× 25), and scattered T‑lymphocytes (g, × 100) within the plaque. The brown bar in the upper left corner is a 1‑mm scale bar
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In vivo study
PET/CT imaging was negative in all patients, regard-
less of whether they were scanned with  [11C]-PBR28 or 
 [18F]-PBR06 (Fig. 5).
Discussion
This study found that  [18F]-PBR06 showed high specific 
binding in vitro in surgical samples of inflamed carotid 
plaques. The binding level was predictably correlated to 
the level of affinity determined by the genotype class, 
but even the participant with low-affinity binding status 
had 13% displaceable binding. Nevertheless, PET scans 
for TSPO in patients detected no sign of inflammation 
in  vivo, suggesting that TSPO imaging is not a viable 
clinical tool for evaluating patients with inflammatory 
vessel disease.
In a similar study, but limited to in vitro data, Fujimura 
and colleagues demonstrated that macrophage and 
inflammatory activity in atherosclerotic plaques could 
be imaged using  [3H]-PK11195 [7].  [18F]-PBR06 and 
 [11C]-PBR28 have equivalent imaging properties in  vivo 
[15], and both have higher affinity for TSPO (Ki = 1.0 nM 
and Ki = 2.5  nM, respectively) than PK11195 
(Ki = 29.2  nM). Therefore, both tracers would be more 
likely to show specific signal in PET studies. In this study, 
however, PET scans with either radioligand showed no 
uptake in patients with carotid stenosis or those with 
large vessel vasculitis. Notably, the carotid plaque of 
one patient (a mixed-affinity binder) was analyzed both 
in vitro and in vivo. While in vitro analysis showed 26% 
specific binding, in vivo imaging was negative.
While most radioligands bind reversibly, irrevers-
ible tracers, like  [18F]-FDG, might have an advantage for 
imaging inflammation in vascular walls because their 
signal-to-background ratio increases over time, while the 
activity in the blood decreases. The signal in the carotid 
plaque may have been masked by the residual plasma 
activity and the specific uptake in blood cells because 
both white cells and platelets express the TSPO recep-
tor. Indeed, as we confirmed in this study (Fig. 4), SMC 
specifically bind TSPO ligands [16] thus adding another 
challenge when using this type of imaging for stratifica-
tion [17].
The limitations of this study are: first, the in vitro study 
concerned only patients with unstable plaques while 
in  vivo studies were performed on patients with ath-
eroma and large vessel vasculitis. Although these condi-
tions have different inflammatory cells infiltrates, both 
are characterized by overexpression of TSPO [18]. Sec-
ond, TSPO polymorphism was unknown for most of our 
Fig. 3 Co‑localization of  [18F]‑PBR06 and CD68 macrophages. a CD68 immunohistochemistry. b fused image of  [18F]‑PBR06 micro‑imaging and 
CD68 staining
Fig. 4 Quantification of  [18F]‑PBR06 specific binding according to 
various areas of atheromatous plaque (whole plaque, macrophages, 
and smooth muscle compartment (SMC)) of all eight samples
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patients (4/6) who underwent PET/CT imaging. How-
ever, the frequency of LAB genotype in the general popu-
lation (9%, [12]) makes the probability of negative results 
due to low-binding negligible (there is 1 chance in 10,000 
that the 4 subjects for whom the genotype is unknown 
are all low-binders). Third, direct TSPO staining was not 
performed, so other markers, such as CD68, were taken 
as a proxy for TSPO expression [8].
Taken together, the results indicate that  [11C]-PBR28 
and  [18F]-PBR06 are not viable clinical tools for imaging 
inflammatory vascular diseases.
Conclusion
Despite good uptake on surgical samples in  vitro, 
 [11C]-PBR28 and  [18F]-PBR06 are not viable clinical tools 
for imaging inflammatory vascular disease.
Acknowledgements
Ioline Henter (NIMH) provided invaluable editorial assistance.
Authors’ contributions
RS analyzed autoradiography results and  [18F]‑PBR06 PET/CT scans, SL 
analyzed immunohistochemistry staining, NB acquired the autoradiography 
images, DV developed and run radiosynthesis of  [18F]‑PBR06, AR performed 
immunohistochemistry, IS enrolled patient and revised the manuscript, 
XB performed surgery of stroke patients, AZ and RIB analyzed  [11C]‑PBR28 
and approved the final version of the manuscript, PZF design, the study, 
was recipient of the funding and revised the manuscript, CM performed 
autoradiography, analyzed results, wrote the manuscript and approved its final 
version. All authors read and approved the final manuscript.
Funding
This study was funded by the University Hospital of Bordeaux (Grant AOI 2014 
to Dr. Paolo Zanotti‑Fregonara) and by the Intramural Research Program of 
the National Institute of Mental Health, National Institutes of Health (Project 
Number ZIAMH002852).
Availability of data and materials
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
Participation was approved by either the ethical committee of the Univer‑
sity of Bordeaux, France (CNIL, declaration number 1858342v0, 11/05/2015 
and CPP DC2015/01 on 12/02/2015 for the in vitro study and 2016/95, on 
21/12/2016 for the in vivo study, Clinical Trial NCT02513589), where the 
 [18F]‑PBR06 scans were conducted, or by the Institutional Review Board (IRB) 
of the National Institute of Mental Health (NIMH) in Bethesda, Maryland, USA 




The authors have no conflict of interest to disclose, financial or otherwise.
Author details
1 Nuclear Medicine Department, University Hospital of Bordeaux, 33076 Bor‑
deaux, France. 2 University of Bordeaux, INCIA, UMR5287, 33400 Talence, 
France. 3 CNRS, INCIA, UMR5287, 33400 Talence, France. 4 Pathology Unit, CH 
Fig. 5 A representative  [18F]‑PBR06 PET/CT (A, C) scan and angio‑CT (B, D) scan. No uptake was observed on the right carotid atheromatous plaque
Page 7 of 7Schollhammer et al. EJNMMI Res           (2021) 11:45  
de Libourne, 33505 Libourne, France. 5 BioTis, Inserm U1026, Bordeaux, France. 
6 Histologic Department, University Hospital of Bordeaux, 33076 Bordeaux, 
France. 7 Neurology Department, University Hospital of Bordeaux, 33076 Bor‑
deaux, France. 8 Vascular Surgery Department, University Hospital of Bordeaux, 
33076 Bordeaux, France. 9 Molecular Imaging Branch, NIMH, Bethesda, MD, 
USA. 10 Nuclear Medicine Department, University Hospital of Bordeaux, Place 
Amélie Raba Léon, 33000 Bordeaux, France. 
Received: 17 February 2021   Accepted: 27 April 2021
References
 1. Sirimarco G, Lavallée PC, Labreuche J, Meseguer E, Cabrejo L, Guidoux C, 
Klein IF, Olivot J‑M, Abboud H, Adraï V, Kusmierek J, Ratani S, Touboul P‑J, 
Mazighi M, Steg PG, Amarenco P. Overlap of diseases underlying ischemic 
stroke. Stroke. 2013;44:2427–33. https:// doi. org/ 10. 1161/ STROK EAHA. 113. 
001363.
 2. Weyand CM, Goronzy JJ. Medium‑ and large‑vessel vasculitis. N Engl J 
Med. 2003;349:160–9. https:// doi. org/ 10. 1056/ NEJMr a0226 94.
 3. Ravikanth R. Role of 18F‑FDG positron emission tomography in carotid 
atherosclerotic plaque imaging: a systematic review. World J Nucl Med. 
2020;19:327–35. https:// doi. org/ 10. 4103/ wjnm. WJNM_ 26_ 20.
 4. Mayer M, Borja AJ, Hancin EC, Auslander T, Revheim ME, Moghbel MC, 
Werner TJ, Alavi A, Rajapakse CS. Imaging atherosclerosis by PET, with 
emphasis on the role of FDG and NaF as potential biomarkers for this 
disorder. Front Physiol. 2020;11:1252. https:// doi. org/ 10. 3389/ fphys. 2020. 
511391.
 5. Kopecky C, Pandzic E, Parmar A, Szajer J, Lee V, Dupuy A, Arthur A, Fok S, 
Whan R, Ryder WJ, Rye K‑A, Cochran BJ. Translocator protein localises to 
CD11b+ macrophages in atherosclerosis. Atherosclerosis. 2019;284:153–
9. https:// doi. org/ 10. 1016/j. ather oscle rosis. 2019. 03. 011.
 6. Cuhlmann S, Gsell W, Van der Heiden K, Habib J, Tremoleda JL, Khalil M, 
Turkheimer F, Meens MJ, Kwak BR, Bird J, Davenport AP, Clark J, Haskard 
D, Krams R, Jones H, Evans PC. In vivo mapping of vascular inflamma‑
tion using the translocator protein tracer 18F‑FEDAA1106. Mol Imaging. 
2014;13:7290.2014.00014. https:// doi. org/ 10. 2310/ 7290. 2014. 00014.
 7. Fujimura Y, Hwang PM, Trout H III, Kozloff L, Imaizumi M, Innis RB, Fujita 
M. Increased peripheral benzodiazepine receptors in arterial plaque of 
patients with atherosclerosis: an autoradiographic study with  [3H]PK 
11195. Atherosclerosis. 2008;201:108–11. https:// doi. org/ 10. 1016/j. ather 
oscle rosis. 2008. 02. 032.
 8. Gaemperli O, Shalhoub J, Owen DRJ, Lamare F, Johansson S, Fouladi N, 
Davies AH, Rimoldi OE, Camici PG. Imaging intraplaque inflammation in 
carotid atherosclerosis with 11C‑PK11195 positron emission tomography/
computed tomography. Eur Heart J. 2012;33:1902–10. https:// doi. org/ 10. 
1093/ eurhe artj/ ehr367.
 9. Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti‑Fregonara P, 
Bertoldo A, Veronese M. The methodology of TSPO imaging with positron 
emission tomography. Biochem Soc Trans. 2015;43:586–92. https:// doi. 
org/ 10. 1042/ BST20 150058.
 10. Cumming P, Burgher B, Patkar O, Breakspear M, Vasdev N, Thomas P, Liu 
G‑J, Banati R. Sifting through the surfeit of neuroinflammation tracers. J 
Cereb Blood Flow Metab. 2018;38:204–24. https:// doi. org/ 10. 1177/ 02716 
78X17 748786.
 11. Zhang H, Xiao J, Zhou J, Tan H, Hu Y, Mao W, Fu Z, Lin Q, Shi H, Cheng D. 
18F‑PBR06 PET/CT imaging for evaluating atherosclerotic plaques linked 
to macrophage infiltration. Nucl Med Commun. 2019;40:370–6. https:// 
doi. org/ 10. 1097/ MNM. 00000 00000 000978.
 12. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, 
Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR, Mooser VE, Mat‑
thews PM, Rabiner EA, Rubio JP. An 18‑kDa translocator protein (TSPO) 
polymorphism explains differences in binding affinity of the PET radioli‑
gand PBR28. J Cereb Blood Flow Metab. 2012;32:1–5. https:// doi. org/ 10. 
1038/ jcbfm. 2011. 147.
 13. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, 
Reading CC, Moertel C. Detection of somatostatin receptors in surgical 
and percutaneous needle biopsy samples of carcinoids and islet cell 
carcinomas. Cancer Res. 1990;50:5969–77.
 14. Morgat C, Schollhammer R, Macgrogan G, Barthe N, Vélasco V, Vimont 
D, Cazeau A‑L, Fernandez P, Hindié E. Comparison of the binding of the 
gastrin‑releasing peptide receptor (GRP‑R) antagonist 68Ga‑RM2 and 18F‑
FDG in breast cancer samples. PLoS ONE. 2019;14:e0210905. https:// doi. 
org/ 10. 1371/ journ al. pone. 02109 05.
 15. Dickstein LP, Zoghbi SS, Fujimura Y, Imaizumi M, Zhang Y, Pike VW, Innis 
RB, Fujita M. Comparison of 18F‑ and 11C‑labeled aryloxyanilide analogs 
to measure translocator protein in human brain using positron emission 
tomography. Eur J Nucl Med Mol Imaging. 2011;38:352–7. https:// doi. org/ 
10. 1007/ s00259‑ 010‑ 1622‑y.
 16. Hellberg S, Silvola JMU, Kiugel M, Liljenbäck H, Savisto N, Li X‑G, Thiele A, 
Lehmann L, Heinrich T, Vollmer S, Hakovirta H, Laine VJO, Ylä‑Herttuala 
S, Knuuti J, Roivainen A, Saraste A. 18‑kDa translocator protein ligand 
18F‑FEMPA: biodistribution and uptake into atherosclerotic plaques 
in mice. J Nucl Cardiol. 2017;24:862–71. https:// doi. org/ 10. 1007/ 
s12350‑ 016‑ 0527‑y.
 17. Wimberley C, Lavisse S, Hillmer A, Hinz R, Turkheimer F, Zanotti‑Fregonara 
P. Kinetic modeling and parameter estimation of TSPO PET imaging in the 
human brain. Eur J Nucl Med Mol Imaging. 2021. https:// doi. org/ 10. 1007/ 
s00259‑ 021‑ 05248‑9.
 18. Lamare F, Hinz R, Gaemperli O, Pugliese F, Mason JC, Spinks T, Camici PG, 
Rimoldi OE. Detection and quantification of large‑vessel inflammation 
with 11C‑(R)‑PK11195 PET/CT. J Nucl Med. 2011;52:33–9. https:// doi. org/ 
10. 2967/ jnumed. 110. 079038.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
